Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, October 5, 2024

Does Spasticity Itself Raise the Cost of Stroke Care 4-Fold?

Well shit, spasticity does not need to be solved per the infuriating opinion of Dr. William M. Landau!

Spasticity After Stroke: Why Bother? Aug. 2004)

Yeah, Bruce Dobkin is a superstar stroke researcher but I think this letter is nit-picking.

  • Dr. Bruce H. Dobkin (15 posts to December 2011)
  • Quit discussing spasticity AND JUST FUCKING CURE IT!

    Does Spasticity Itself Raise the Cost of Stroke Care 4-Fold?

  • To the Editor:
    The report from Lundstrom et al1 headlines a relationship between spasticity and higher direct costs of stroke care over the first year after onset. The authors seem to be putting the cart’s contents, 1 of which is spasticity, before the horse of sensorimotor impairment. The authors used a modified Ashworth Score of ≥1 in any 1 of 7 arm and leg joints as the measure of spasticity. The modified Ashworth Score is a 6-point ordinal scale of resistance to passive movement across a joint, which can arise from reflexive clasp-knife resistance and from changes in connective tissues of the joint associated with severity of paresis, nonuse, and contracture. It is often used in studies, but its validity and reliability may be less than necessary to reflect a physiologically meaningful measure.2 Clinicians involved in the care of patients with chronic stroke would not consider a modified Ashworth Score in any 1 joint of <3 to suggest a clinically important problem. No evidence exists that the modified Ashworth Score cutoff used for this study’s retrospective, database-driven findings could be detrimental after stroke. So what underlies the relationship described?
    The authors found a significantly higher National Institutes of Health Stroke Scale score in the group considered to have any degree of spasticity. It would seem, then, that they would want to examine for a correlation between cost of care and level of impairment based on the National Institutes of Health Stroke Scale. They did show that poorer modified Rankin Scale scores (which intermix aspects of impairment and disability) were significantly related to higher costs. If indeed, greater resistance to passive movement across a singe joint has a relationship to cost, the primary relationship is probably to the degree of sensorimotor impairment that induces greater disability and, in turn, higher in-hospital costs from complications of greater impairment such as immobility.
    The discussion from the authors seems to repudiate the primacy of their correlation. If “our study does not provide evidence that spasticity as such is responsible for the (4-fold) increase of costs” and “spasticity reflects a more severe motor disorder,” how can the authors suggest that their data offer, at best, a baseline for “the cost-effectiveness of interventions, including botulinum toxin” … ? This particular intervention is likely to drive up costs if injected into patients with a modified Ashworth Score <3 but will not alter sensorimotor impairments. From a healthcare priority point of view, their findings suggest the need for more outpatient physiotherapy, which was provided to only 4% of their subjects. A rehabilitation intervention to maintain range of motion, prevent painful contractures and dystonic postures, and to improve motor control and skills might reduce disability, costs, and burden of care for those who are most impaired by paresis.

    References

    1.
    Lundstrom E, Smits A, Borg J, Terent A. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event. Stroke. 2010; 41: 319–324.

    No comments:

    Post a Comment